Revolutionary Trial Aims to Turn Back Time for Senior Dogs: Meet Boo, the Whippet Pioneering a New Era of Canine Longevity!
Loyal, the biotech trailblazer in pet longevity, has embarked on a groundbreaking journey with the launch of its STAY study, administering the first dose of the promising LOY-002 drug to Boo, an 11-year-old Whippet. This monumental trial is not just a medical first but a beacon of hope for pet owners dreaming of more quality time with their aging furry friends.
What to know about anti-aging medication in development that could help dogs live longer
The Center for Veterinary Medicine at the FDA has reviewed Loyal’s data, results, and scientific arguments and determined they provide reasonable expectation of the drug’s effectiveness to extend canine lifespan and healthspan. Pending successful completion of the Manufacturing and Safety sections, Loyal will receive conditional approval for LOY-001, allowing them to market the drug for large-dog lifespan extension.